biostudies-literatureUnknown22(1)Tang X<h4>Background</h4>The prevalence of Helicobacter pylori antibiotic susceptibility in the Tibet Autonomous Region, China is not determined. This study aimed to evaluate the antibiotic resistance patterns of H. pylori isolates there.<h4>Results</h4>A total of 153 (38.5%) H. pylori strains were successfully isolated from 397 patients in People's Hospital of Tibet Autonomous Region, China. The overall resistance rates were as follows: clarithromycin (27.4%), levofloxacin (31.3%), metronidazole (86.2%), amoxicillin (15.6%), tetracycline (0%), furazolidone (0.6%), and rifampicin (73.2%). Only 2.0% of H. pylori isolates were susceptible to all tested antimicrobials, with mono resistance, dual resistance, triple resistance, quadruple resistance, and quintuple resistance being 18.3%, 44.4%, 18.3%,BMC microbiology196https://www.ebi.ac.uk/biostudies/studies/S-EPMC9375320biostudies-literatureAntibiotic resistance patterns of Helicobacter pylori strains isolated from the Tibet Autonomous Region, China.PMC9375320Li HMarshall BJShen YSong XWang ZTang XBenghezal MTang HfalseAntibiotic resistance patterns of Helicobacter pylori strains isolated from the Tibet Autonomous Region, China.<h4>Background</h4>The prevalence of Helicobacter pylori antibiotic susceptibility in the Tibet Autonomous Region, China is not determined. This study aimed to evaluate the antibiotic resistance patterns of H. pylori isolates there.<h4>Results</h4>A total of 153 (38.5%) H. pylori strains were successfully isolated from 397 patients in People's Hospital of Tibet Autonomous Region, China. The overall resistance rates were as follows: clarithromycin (27.4%), levofloxacin (31.3%), metronidazole (86.2%), amoxicillin (15.6%), tetracycline (0%), furazolidone (0.6%), and rifampicin (73.2%). Only 2.0% of H. pylori isolates were susceptible to all tested antimicrobials, with mono resistance, dual resistance, triple resistance, quadruple resistance, and quintuple resistance being 18.3%, 44.4%, 18.3%,2022-01-01T00:00:00Z2022 Aug2025-04-19T18:51:01.883Z2025-04-19T18:51:01.883ZS-EPMC93753203596401110.1186/s12866-022-02613-y